Elotuzumab-induced interstitial lung disease: the first case report

Dermatomyositis occurs extremely rarely during pregnancy. A number of studies in the published literature have documented how the outcome of pregnancy is poor for both mother and fetus. The present case study reports on a patient who was diagnosed with clinically amyopathic dermatomyositis complicated by interstitial lung disease during pregnancy, and was successfully treated with a combined immunosuppressant regimen. To the best of the authors’ knowledge, this is the first case study detailing how a pregnant woman with clinically amyopathic dermatomyositis with positive anti-melanoma differentiation-associated gene 5 antibody achieved complete remission after early intervention of combined immunosuppressive therapy without residual pulmonary interstitial changes.

Download Full-text

Interstitial Lung Disease in a Patient Treated with Denosumab

European Journal of Case Reports in Internal Medicine ◽

10.12890/2019_001131 ◽

2019 ◽

Author(s):

Ana Campo Ruiz ◽

Miguel F Carrascosa ◽

Sergio Tapia Concha ◽

Anibal Hernández Gil ◽

Juan García Rivero

Keyword(s):

Case Report ◽

Interstitial Lung Disease ◽

Adverse Effects ◽

Lung Disease ◽

English Literature ◽

Osteonecrosis Of The Jaw ◽

Femur Fractures ◽

First Case ◽

Atypical Femur Fractures ◽

Clinically Significant

Denosumab is an antiresorptive agent widely used for treating osteoporosis. Atypical femur fractures, osteonecrosis of the jaw and hypocalcaemia are well-known possible adverse effects of this drug. We present, to our knowledge, the first case report in the English literature of clinically significant interstitial lung disease likely related to denosumab.

Download Full-text

Acceleration of interstitial lung disease induced by raltitrexed

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155219887213 ◽

2019 ◽

Vol 26 (5) ◽

pp. 1241-1243 ◽

Cited By ~ 1

Author(s):

Sarah Howlett ◽

Raminder Aul ◽

Mark Hill ◽

David J Pinato

Keyword(s):

Case Report ◽

Interstitial Lung Disease ◽

Lung Disease ◽

Thymidylate Synthase ◽

Colorectal Adenocarcinoma ◽

Preoperative Staging ◽

Rapid Progression ◽

Lung Function Tests ◽

Clinical Pattern ◽

Significant Acceleration

Introduction Raltitrexed is a folate analogue, which selectively inhibits thymidylate synthase, used in the treatment of colorectal carcinoma. Common side effects include asthenia and gastrointestinal and haematological toxicities. Case report We present the case of a 74-year-old gentleman with incidental mild interstitial lung disease on preoperative staging CT Chest who developed acute breathlessness whilst undergoing adjuvant raltitrexed treatment for a completely excised colorectal adenocarcinoma. Management and outcome Discontinuation of raltitrexed and a course of steroid therapy resulted in resolution of symptoms, mirrored by an improvement in lung function tests. Discussion The clinical pattern of rapid progression with steroid response highlights the potential for significant acceleration of interstitial lung disease by raltitrexed.

Download Full-text